CYAD-N2T-002 (THINK) (R/R)

A multinational, open-label, dose escalation Phase I/II study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types (THINK)

Study treatments

• Administration of NKR-2 cells intravenous

Inclusion criteria

• Age 18 years or older
• Patient with Acute Myeloid Leukemia/Myelodysplasia or Multiple Myeloma
• Disease must be measurable according to the corresponding guidelines
• ECOG score of 0-1
• Patient with adequate bone marrow reserve, hepatic and renal functions

Exclusion criteria

• Patient with a tumor metastasis in the central nervous system
• Patients who have received another cancer therapy within 2 weeks before the planned day for the apheresis
• Patients who receive or are planned to receive any other investigational product within the 3 weeks before the planned day for the first NKR-2 administration
• Patients who are planned to receive concurrent growth factor, systemic steroid or other immunosuppressive therapy or cytotoxic agent
• Patients who have received other cell therapies
• Patients who underwent major surgery within 4 weeks before the planned day for the first NKR-2 administration

Participating sites

• Ghent University Hospital
• Institut Jules Bordet